Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
leslunier, the Provista Diagnostic options were executed. After I provide proof in the filings, I hope this satisfies your continuing suspicions that GC is lying to shareholders. There are numerous examples of where this was reported and supported in the various filings. No more questions, as I am done researching this to address your concerns. There is still the question of how $3M + $7.5M adds to $10M, but I did see reference throughout to a number of smaller amounts and fees paid to Provista that were likely credited to the final price, so I suspect that's where the $0.5M difference lies. I spent way too much time on this already and I'm not going to dig those up to try explain the difference. Doesn't matter to me. I'm satisfied the transaction was legit. No more questions, please.
This is the timeline of relevant filings and events.
1/9/20
News release announcing option to acquire Provista Diagnostics
https://investor.todosmedical.com/news-events/press-releases/detail/35/todos-medical-enters-into-exclusive-option-agreement-to
1/10/20
Form 6-K filing describing Provista Diagnostics acquisition price of $10M.
- $1M paid for consideration of option to acquire, expiring 3/31/20
- $1M additional payment required to extend option to 6/30/20
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001213900-20-000685/0001213900-20-000685.pdf
2/1/20
Schedule 13G filed by Strategic Investment Holdings listing ownership of 17,096,096 Todos shares.
Transaction date is 1/21/20. Total ownership listed as 17,091,096 shares.
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-20-002837/0001493152-20-002837.pdf
4/10/20
Schedule 13G filed by Strategic Investment Holdings listing ownership of another 13,008,976 Todos shares.
Transaction date is 4/1/20. Total ownership listed as 30,100,072 shares.
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-20-006190/0001493152-20-006190.pdf
5/11/20
Form 6-K filed providing voting results of the Special Meeting of Shareholders. Proposal 2 is approved:
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-20-008246/0001493152-20-008246.pdf
6/15/20
Form 20-F (Annual Report) filed.
From page 95:
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-20-011206/0001493152-20-011206.pdf
7/15/20
Schedule 13D filed by Strategic Investment Holdings listing ownership of another 18,608,113 Todos shares.
Transaction date is 7/7/20. Total ownership is listed as 48,708,185 shares.
I assume this is the option to extend acquisition deadline to 2021. Look to future filings for explanation.
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-20-013368/0001493152-20-013368.pdf
4/21/21
Form 10-K (Annual Report) filed.
From page F-64:
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-21-009396/0001493152-21-009396.pdf
The 3 filings of share ownership by Strategic Investment Holdings align with the 3 option payments of $1M each. Again, I expect the full explanation of this acquisition to be in the upcoming quarterly report.
werd, your posts suggest you believe Pfizer understands the molecular target of the 3CL protease enzyme better than Todos. Fact is, Todos partnered with NLC Pharma, which probably has as much experience and research with the 3C and 3CL protease enzymes as does Pfizer. It is my belief they are at least on even footing, and perhaps the NLC Pharma joint venture gives Todos the advantage over Pfizer, since the Tollovir product has also been shown to suppress the cytokine storm that is a dangerous immune system response.
I do agree with you, however, that a buyout offer may be at least a possibility, but probably after trial results are published (but then at a much higher price if results are good).
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
https://investor.todosmedical.com/news-events/press-releases/detail/125/todos-medical-completes-validation-of-cpass-neutralizing
• Company sees a significant market opportunity for cPass as a potential immunity monitoring tool for schools, businesses and healthcare providers to determine the future need for booster shots or other measures to prevent virus spread
• CEO to discuss cPass on Fox Business Network ‘Varney & Company’ at 11:40 am on August 23, 2021
• Validation paves the way for launch of cPass testing at Provista in September 2021
New York, NY, and Tel Aviv, ISRAEL, Aug. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the cPass Neutralizing Antibody Blood Test into production and expects to launch cPass in September 2021. The cPass ELISA blood test has received Emergency Use Authorization from the FDA for the detection of neutralizing antibodies (NAbs) that will allow healthcare professionals and patients to monitor key biomarkers of COVID-19 immunity.
Todos Medical CEO Gerald Commissiong has been scheduled to appear on Fox Business Network show Varney & Company at 11:40 am ET on Monday, August 23, 2021 to discuss cPass and how it is expected to empower healthcare professionals and patients with a new tool to monitor their immunity to COVID-19 as booster shots are being rolled out in the United States. There are a rising number of breakthrough infections and the cPass may represent a way to identify those at greatest risk.
“As we begin to see the impact of breakthrough infections with the Delta variant throughout the United States, we expect the FDA to authorize widespread access to booster shots in the weeks ahead,” said Gerald Commissiong, President & CEO of Todos Medical. “Vaccinated and unvaccinated patients are certainly looking for solutions to understand their level of risk to the Delta variant. Likewise, many physicians are looking for objective data to help them manage their patients. cPass will help provide this key information on neutralizing antibody levels in vaccinated patients and patients that acquired their immunity through natural infection. The test allows both the patient and the physician to be more informed with respect to the patient’s existing level of COVID-19 immunity. The White House push to get people vaccinated quickly in the second quarter displaced the testing volume that was expected by many COVID testing labs and so they retooled back to their pre-pandemic business models centered on non-COVID sample volume. We chose a different path for Provista and sought to invest in automation to prepare for the next wave of the disease and the tremendous monitoring opportunity we felt it represented. We saw our local community in the greater Atlanta area ravaged by the first and second waves of the disease due to a lack of testing capability, and felt we had an obligation to be more proactive to fulfill the market need just as schools and business prepare to open for the fall. We think cPass could play a pivotal role in helping roll out booster shots to those at-risk in the months ahead.
Todos sees a large market opportunity developing for cPass that will expand upon the COVID-19 PCR testing market that rapidly developed into an $80 billion market worldwide in 2020. Provista Diagnostics has the automation in place to do up to 20,000 PCR tests and over 1,500 cPass tests per day. The CMS reimbursement rate per PCR test is $100 and per cPass test is at least $79. Immune monitoring will likely be the primary driver of COVID-19 testing growth going forward. To date, over 200 million people in the United States have received at least one COVID-19 vaccine dose, with the majority of the doses having been administered to older populations and the immunocompromised for whom booster shots are being recommended. As time advances, and more and more individuals are 6 months and beyond from their initial vaccine dose, it will become increasingly important for individuals, schools, businesses and healthcare providers to asses and monitor neutralizing antibody levels in order to make data-driven decisions with respect to booster shots and behavioral changes.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain (COVID-19) testing materials and supplies. The agreements cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID-19 antibody and antigen testing kits.
Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate and Investor Contact:
Richard Galterio
Todos Medical
732-642-7770
rich.g@todosmedical.com
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
https://investor.todosmedical.com/news-events/press-releases/detail/124/todos-medical-ceo-to-appear-on-fox-business-network-varney
New York, NY, and Tel Aviv, ISRAEL, Aug. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Gerald Commissiong, CEO of Todos Medical, is scheduled to appear on Varney & Co. on the Fox Business Network at 11:40 AM Eastern Time today. Mr. Commissiong will discuss the planned launch of cPass neutralizing antibody testing at the Company’s Provista Diagnostics laboratory and how it is expected to empower healthcare professionals and patients with a new tool to monitor their immunity to COVID-19 as booster shots are being rolled out in the United States.
The segment can also be viewed online at: Varney & Co| Fox Business.
Varney & Co. is a daily morning news/talk program hosted by British-American economic and political commentator Stuart Varney on Fox Business on weekdays 9 AM – 12 PM ET. The show includes market coverage, current events coverage, and interviews and commentary with Wall Street experts.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain (COVID-19) testing materials and supplies. The agreements cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID-19 antibody and antigen testing kits.
Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate and Investor Contact:
Richard Galterio
Todos Medical
732-642-7770
rich.g@todosmedical.com
You have the option to skip over those posts, as they are clearly labeled as CEO on Twitter with the date. I intend to continue to post CEO tweets here because they are relevant to the company's business. Some readers here do not have Twitter accounts, including yourself. No one is forcing your to read those Twitter posts.
One would think you would welcome the Twitter reposts, as it provides additional things to pick apart to support the theory that GC is lying to us. It must be difficult being a shareholder in a company where one believes the CEO is lying to shareholders, and yet continuing to hold shares, unable to sell and move on. I can only imagine the stress that creates.
Or, just put me on IGNORE as I've suggested. i don't care which. Either option requires some amount of self control. Perhaps that's the real issue.
So now you don't want to see GC's Twitter posts here?
You keep posting twitter tweets that GC posts. This is TODOS board not twitter.
I did stop posting for a time, and then several posters asked me to return as they found value in my posts, so I started posting again, but removed myself as board moderator. I never posted that I had sold and then magically returned posting as a shareholder.
I don't recall seeing any posts asking you to stay after your announced departure from the board.
There was no 8-K on 4/22/21. The 8-K issued on 4/23/21 describing the transaction listed $7.5M. I'm done discussing this. I have asked the CEO about the perceived discrepancy and he has answered to my satisfaction, and it is backed up in the filings. Continue to believe there is deception related to that sale if you want.
I know more about Amarantus than you realize. I have several friends who were invested in Amarantus back then. I know an investor on an AMBS conference call was identified as a stock analyst by the host and failed to correct that error. I suppose they felt a higher level of importance being identified as an analyst.
I know the same investor claimed to have a Come to Jesus call with Gerald via a private phone call and afterward reached out to other investors pleading with them to BUY BUY BUY shares stating the "whales" were buying shares, and then was very upset when most board members called BS and refused to go along with his ploy, having already identified this investor as a flipper.
I know the same investor painted such a fantastic picture of the AMBS story on the boards and pulled in many novice investors and never acknowledged any responsibility for this or his decision to invest $100K+ in a high-risk penny stock, and puts 100% of the blame on the CEO when his road to riches failed to pan out, and continues to post trashing the CEO even years later.
Sound like anyone you know?
This is the board for Todos Medical. Choosing not to invest based on past experience with the same CEO is one's right, but constantly attacking the CEO based on a prior foolish investment in a penny stock points to other issues.
This investor should get some counseling and learn to move on. Just my humble opinion.
Todos released news on 1/9/20 announcing the exclusive option to acquire Provista Diagnostics.
Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes
https://investor.todosmedical.com/news-events/press-releases/detail/35/todos-medical-enters-into-exclusive-option-agreement-to
This was followed with a 6-K filing on 1/10/20 which identified the total price agreed on.
On January 6, 2020, Todos Medical Ltd. (the “Company”) entered into an exclusive option agreement (the “Agreement”) with Strategic Investment Holdings, LLC, Ascenda BioSciences LLC and Provista Diagnostics, Inc. (“Provista”) pursuant to which the Company received an exclusive option until March 31, 2020 to acquire Provista for a number of ordinary shares of the Company equal to a value of $10,000,000 at the volume weighted average price (“VWAP”) of the last 20 trading days prior to exercise of the option, provided that the Company’s ordinary shares are listed on a national exchange at the time of the closing of the transaction. Consideration for the option is the issuance of a number of ordinary shares of the Company equal to a value of $1,000,000 at the VWAP of the last 20 trading days prior to execution of the Agreement, The option may be extended by the Company to June 30, 2020 by the issuance by the Company of an additional number of ordinary shares equal to a value of $1,000,000 at the VWAP of the last 20 trading days prior to exercising the extension.
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001213900-20-000685/0001213900-20-000685.pdf
How is this misleading? Because JP says so?
As to why I didn't post any follow-up questions.... it's because I didn't have any. GC responded quickly because when I logged into Twitter to post I saw he was actively posting and when he responded I thanked him for his quick reply. What does this mean? It means he was actively posting at the time of my question and he responded within a few minutes. Don't try to create a conspiracy where none exists. You are free to create your own Twitter account (it's free) and ask him direct questions yourself instead of relying on others to do the work for you. Give it a try. But as with anyone, it pays to be polite and diplomatic... if the Twitter post accuses him of lying and criminal behavior, expect to be ignored.
In my younger days, I was more foolish with money than I am today. We all learn from our experiences. Hopefully we become wiser regarding our investments but it doesn't happen for everyone. Nowadays I invest more than half of my income, which was only possible after becoming totally debt-free, in great-performing mutual funds and select stock recommendations based on the Motley Fool Stock Advisor. Those have been performing pretty well for me. I only have two penny stock investment: TOMDF and MONI. I probably have too much in Todos but a much smaller amount in MONI. I am not buying more shares in either but focusing one the earlier mentioned investments. Both TOMDF and MONI are high risk and I am currently underwater on both.
Sorry, but I don't believe for a minute you are "moving on", as this claim has been made several times before and hasn't happened yet. At one time there was a post claiming to have totally sold out which later proved to be inaccurate. GC isn't the only one with the perceived credibility problem, in my opinion.
GLTY in whatever option you choose.
CEO Blogs... all discussions about goals, directions, expectations... clearly protected by the Safe Harbor laws and as such should be regarded as such in making investment decisions by an investor... except those who are foolish with their money, or who are in way over their head and should stick to mutual funds.
Who is to blame when someone invests $100K+ in a penny stock and loses? The CEO? Every CEO hypes their company and their intended goals and direction. Investors should know how to distinguish facts from fiction that may or may not pan out, and invest accordingly. Sorry, but sounds like a get-rich-quick minded investor who invested too much based on hopes and dreams, not on actual performance. That's on the investor, not the CEO. The CEO hasn't been investigated or accused or convicted of a crime, except by a disgruntled investor on a message board. That tells the whole story.
I am only invested in two penny stocks... TOMDF and MONI. MONI came to my attention based on your posts and I started following the board. I invested no more than I can afford to lose, and I won't be blaming the CEO if it doesn't pan out. I accept responsibility for my investment decisions.
Dude, I'm just an investor posting news and opinions about a company I'm invested in. I don't post on boards where I'm not invested. This board certainly is not a world stage.
Someone is posting rants on a public message board for a company in which they own no shares. The posts generalize and provide no specifics as to whether these "lies" are based on actual financials or filing deceptions, or based on strategies, goals, or predictions that failed to materialize.
All I'm asking for is specifics with that distinction. Surely someone seemingly so well-versed in Gerald's past can provide specifics instead of generalizations. If they won't provide, then that kinda tends to leave readers with a different opinion about the poster's motives, doesn't it?
Or one could focus their energy on boards where they actually own shares.
All of US... you know, the readers of this board, those you want to read your posts and your opinions of GC.
I'm sure everyone would enjoy knowing whether your extreme dislike of our CEO is based on actual lies he made in filings (the only thing that REALLY matters, according to you) or foolish over-investing by an investor based on predictions and the non-factual stuff intended to be protected by the Safe Harbor statements you believe protects GC (as it does every public company CEO).
Your efforts to steer future investors clear of Todos might be more effective if you spelled out specifics of factual lies vs. predictions or expectations that didn't pan out. You understand... the stuff investors can actually verify with some DD.
So tell us, were your prior investments in Amarantus with Gerald at the helm based on lies or inaccurate figures in filings (you know, the stuff that REALLY matters), or were they based on predictions that failed to materialize? Did Gerald reveal things to you in your private communications that you took to be facts given in confidence (and in violation of law) that were later revealed to be false?
What made you invest so much with Gerald in Amarantus when there were little or no revenues ever reported in the filings, only acquisitions and testing of potential assets that were speculative until proven effective? Spell it out for us, please.
Again, this was a penny stock up until the time of their reverse split.
So, you are saying you DID listen to the entire interview where GC clearly discussed the acquisition of Provista Labs, but still posted the photo of the guy heading up Provista Labs from an earlier video as part of your rant?
SEC filings of financials and contracts/agreements provide the facts. Forward-looking statements provide goals and predictions that may not pan out. Some here clearly confuse facts with predictions. If someone sets and discusses a goal or predicts an outcome and it doesn't work out, that's not a lie. Investors should understand the difference and the risk associated with investing based on predictions vs facts. Unfortunately, some don't and invest far too much based on predictions, and them blame the CEO entirely when they lose money and fail to become wealthy as they hoped they would. Some become so enthusiastic in their investment based on goals and predictions they engage family, friends, and others on message boards encouraging them to invest also. I suppose claiming the CEO lied to them is how they try to save face, instead of accepting the fact they invested entirely based on speculation and predictions of how things would turn out. That's another reason the share price was penny stock range when they invested, since it was priced accordingly in the market based on the risk and lack of actual financials to support a higher share price.
From Investopedia:
https://www.investopedia.com/terms/f/forward-looking.asp
Outstanding Shares Update - 8/20/21
https://www.otcmarkets.com/stock/tomdf/security
The concerns of a non-shareholder are truly touching. Thanks for sharing.
In case you didn't know, the guy in the last photo was over Provista Labs, which Todos acquired, so it is inappropriate to include that in this axe-grinding rant.
Listening to the actual interview instead of posting blindly about it can help to prevent these kinds of obvious errors. The interview was 31 minutes in length. Probably only an actual shareholder would feel the time to view it was worth the effort. But thanks again for pointing out things shareholders already know, yet choose to remain invested.
Todos Medical Presentation at Emerging Growth Conference - 8/18/21
CEO on Newsy Interview
Why do you need a booster shot now?
— Scripps News (@scrippsnews) August 18, 2021
CEO of Todos Medical, @G_Commish explains the science behind booster shots, what's in the COVID-19 vaccine and why people who received the Johnson & Johnson vaccine don't need a second or third shot. pic.twitter.com/tFo8VlmpjU
How about another Come to Jesus chat so we can rally the shareholders. Do you still have Gerald on speed dial? Tell us again how the "whales" are buying shares and beg longs to support the share price while you secretly unload your shares.
You can't make this stuff up!!
BTW, he's not "my guy". I'm a shareholder posting info about the company. Nothing more. I don't come here to post as a non-shareholder who continues to be infatuated with Gerald. I think you sat next to him at a Amarantus shareholders meeting, probably making google eyes at him.
The Dominant Delta Variant and Lambda Variant Lurking in the Shadows
by Gerald Commissiong
Published on August 11, 2021
https://www.linkedin.com/pulse/dominant-delta-variant-lambda-lurking-shadows-gerald-commissiong
The Gerald addiction continues. Sad.
FORM 12b-25 NOTIFICATION OF LATE FILING
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-21-020136/0001493152-21-020136.pdf
Due Monday 16th. No filing deadlines are on a weekend.
Outstanding Shares Update - 9/13/21
https://www.otcmarkets.com/stock/tomdf/security